Bifogade filer
Pledpharma Nomination Committee 201020
Kurs
-2,78%
Likviditet
2,14 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-05-07 | N/A | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2025-05-06 | N/A | Årsstämma |
| 2025-04-30 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-25 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2024-05-06 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2023-04-27 | - | Årsstämma |
| 2023-04-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-11-08 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | Årsstämma |
| 2022-05-11 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2022-04-26 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-13 | - | Extra Bolagsstämma 2022 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-12-11 | - | Extra Bolagsstämma 2020 |
| 2020-11-04 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-24 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2020-04-23 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-18 | - | Bokslutskommuniké 2019 |
| 2019-10-23 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-05-06 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-10-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-25 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2018-04-24 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-10-20 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-26 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2017-04-25 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2017-02-10 | - | Extra Bolagsstämma 2017 |
| 2016-11-07 | - | Extra Bolagsstämma 2016 |
| 2016-10-20 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-15 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2016-04-14 | - | Årsstämma |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2015-10-20 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-18 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-15 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2015-04-14 | - | Årsstämma |
| 2015-02-17 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Extra Bolagsstämma 2014 |
| 2014-10-24 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-28 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-25 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-09 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2014-04-08 | - | Årsstämma |
| 2014-02-19 | - | Bokslutskommuniké 2013 |
| 2013-10-25 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-29 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-19 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2013-04-18 | - | Extra Bolagsstämma 2013 |
| 2013-04-18 | - | Årsstämma |
| 2013-04-18 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-10-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-30 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2012-03-29 | - | Årsstämma |
| 2012-02-17 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-25 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, October 20, 2020. The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 29, 2021. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.
The following members have been appointed by the subsequent shareholders:
Cidro Förvaltning AB: Peter Lindell
Nortal Investments AB: Staffan Persson
Fjärde AP-fonden: Jannis Kitsakis
In total, the Nomination Committee represents approx. 31% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Staffan Persson and Jannis Kitsakis are also independent in relation to Cidro Förvaltning AB, which is the largest shareholder in the company in terms of votes.
The Nomination Committee has elected Peter Lindell as chairman. Håkan Åström, Chairman of PledPharma have been nominated to co-opt to the Nomination Committee.
PledPharma AB (publ) signed an agreement to acquire all outstanding shares in Rare Thyroid Therapeutics International AB (RTT) on October 5, 2020. The transaction is expected to be completed on November 3, 2020.
As a part of the share purchase price the former shareholders in RTT will receive 63,773,345 new shares in PledPharma trough an issue of Consideration Shares.
On the occasion of the acquisition of RTT, PledPharma carries out a rights issue of a maximum of 38,238,085 shares. The subscription period is 9 November to 23 November 2020.
The composition of the three largest shareholders will be amended due to the issue of the Consideration shares and the Rights Issue. Therefore, the composition of the future Nomination Committee will also change to reflect the new ownership. PledPharma intends to return with information on the composition of the new Nomination Committee after the new ownership has been registered.
The Committee's assignment is to present proposals regarding Chairman and other members of the, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2022.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com
For further information, please contact:
Marie-Louise Alamaa, Interim CFO
Tel. 070 861 88 42
marie-louise.alamaa@pledpharma.se
About PledPharma
PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need.
The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of a pivotal Phase II/III study for US/EU regulatory submission is being finalized through ongoing regulatory interactions. Aladote® has been granted Orphan Drug Designation in the US.
The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx is warranted via strategic partnerships and is expected to be announced in Q4 2020.
PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/